Literature DB >> 18841046

Editorial review: targets for glioma treatment: from bench to bedside.

Marc Sanson.   

Abstract

PURPOSE OF REVIEW: Progress in molecular mechanisms and pathogenesis of malignant gliomas opens new therapeutic possibilities. RECENT
FINDINGS: Recent developments in the field of tumour biology have elucidated signalling pathways and genes involved in the development of gliomas, which represent new potential therapeutic targets, and many targeted therapies are currently being tested in clinical trials. Except for the antiangiogenic drugs, the results have been modest, because of the heterogeneity of malignant gliomas and redundant pathways, suggesting that combination therapies may be more appropriate. The recent finding that only a minority of tumour cells are capable of self-renewal (tumour stem cells) leads to focus on genes specifically involved in stem cell self-renewal and proliferation.
SUMMARY: Antiangiogenic drugs already have proved efficacy. Targeting of tumour-specific alterations and drugs more specifically directed against tumour stem cells may provide significant progress in future treatment of gliomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841046     DOI: 10.1097/CCO.0b013e328313e188

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  3 in total

1.  The cytotoxic effect of β-elemene against malignant glioma is enhanced by base-excision repair inhibitor methoxyamine.

Authors:  Yongjian Zhu; Jue Hu; Fang Shen; Hong Shen; Weiguo Liu; Jianmin Zhang
Journal:  J Neurooncol       Date:  2013-05-23       Impact factor: 4.130

Review 2.  ERBB signaling in CTCs of ovarian cancer and glioblastoma.

Authors:  Anjali Geethadevi; Deepak Parashar; Erin Bishop; Sunila Pradeep; Pradeep Chaluvally-Raghavan
Journal:  Genes Cancer       Date:  2017-11

3.  Elevated IQGAP1 and CDC42 levels correlate with tumor malignancy of human glioma.

Authors:  Xiaobo Cui; Laixiao Song; Yunfei Bai; Yaping Wang; Boqian Wang; Wei Wang
Journal:  Oncol Rep       Date:  2016-12-29       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.